Trial · NCT01551693
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
NCT01551693, Phase 2, Terminated, Dana-Farber Cancer Institute; results first posted 2017-04-12
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma. Trials, record NCT01551693. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01551693
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
- NCT number
- NCT01551693
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- Dana-Farber Cancer Institute
- Conditions
- Melanoma
- Interventions
- STA-9090
- First posted
- 2012-03-13
- Last updated
- 2017-04-12
- Results first posted
- 2017-04-12
- Limitations and caveats
- The study was terminated early due to weak accrual.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-month Progression-Free Survival Rate | Disease was evaluated radiologically at baseline and every 8 weeks on treatment; Treatment continued until evidence of disease progression or unacceptable toxicity. Relevant for this endpoint was disease status at 6 months. | 6-month progression-free survival rate was defined as the proportion of patients absent death or progression based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST) before 6 months. Per RECIST 1.0 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. |
| Secondary | Best Overall Response | Disease was evaluated radiologically at baseline and every 8 weeks on treatment. Median (range) treatment duration was 1 cycle/4 weeks (1-2 cycles; 4-8 weeks). | Best overall response (BOR) on treatment was based on RECIST 1.0 criteria. For target lesions, complete response (CR) is complete disappearance of all target lesions and partial response (PR) is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. CR or PR confirmation required within 4 weeks. Progressive disease (PD) is at least a 20% increase in the sum LD of target lesions from smallest sum LD as reference or the appearance of one or more new lesions. Stable disease (SD) is neither meeting PR or PD. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. CR is disappearance of all non-target lesions. |
| Secondary | Overall Survival | Patients were followed every 4 weeks for survival until death, lost to follow-up or study closure (approximately 6 months after the last patient ended treatment). In this study cohort, patients were followed up to 13 weeks. | Overall survival is defined as the time from study entry to death or date last known alive and estimated using Kaplan-Meier (KM) methods. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 6-month Progression-Free Survival Rate | Disease was evaluated radiologically at baseline and every 8 weeks on treatment; Treatment continued until evidence of disease progression or unacceptable toxicity. Relevant for this endpoint was disease status at 6 months. | proportion of participants | NUMBER | |
| SECONDARY | Best Overall Response | Disease was evaluated radiologically at baseline and every 8 weeks on treatment. Median (range) treatment duration was 1 cycle/4 weeks (1-2 cycles; 4-8 weeks). | participants | NUMBER | |
| SECONDARY | Overall Survival | Patients were followed every 4 weeks for survival until death, lost to follow-up or study closure (approximately 6 months after the last patient ended treatment). In this study cohort, patients were followed up to 13 weeks. | Overall survival was not estimated given the limited sample size. |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 6-month Progression-Free Survival Rate | STA-9090 Cohort A | 0.0 | proportion of participants | ||
| 6-month Progression-Free Survival Rate | STA-9090 Cohort B | 0.0 | proportion of participants | ||
| Best Overall Response | STA-9090 Cohort A | Progressive Disease | 1 | participants | |
| Best Overall Response | STA-9090 Cohort B | Progressive Disease | 1 | participants | |
| Best Overall Response | STA-9090 Cohort A | Unevaluable | 0 | participants | |
| Best Overall Response | STA-9090 Cohort B | Unevaluable | 1 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | STA-9090 Cohort A | 1 | |
| Overall Study | STARTED | STA-9090 Cohort B | 2 | |
| Overall Study | COMPLETED | STA-9090 Cohort A | 0 | |
| Overall Study | COMPLETED | STA-9090 Cohort B | 0 | |
| Overall Study | NOT COMPLETED | STA-9090 Cohort A | 1 | |
| Overall Study | NOT COMPLETED | STA-9090 Cohort B | 2 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | STA-9090 Cohort A | 0 | 1 | |
| other | Anemia | Blood and lymphatic system disorders | STA-9090 Cohort B | 1 | 2 | |
| other | Diarrhea | Gastrointestinal disorders | STA-9090 Cohort A | 0 | 1 | |
| other | Diarrhea | Gastrointestinal disorders | STA-9090 Cohort B | 1 | 2 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | STA-9090 Cohort A | 0 | 1 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | STA-9090 Cohort B | 1 | 2 | |
| other | Hypoxia | Respiratory, thoracic and mediastinal disorders | STA-9090 Cohort A | 0 | 1 | |
| other | Hypoxia | Respiratory, thoracic and mediastinal disorders | STA-9090 Cohort B | 1 | 2 | |
| serious | Alkaline phosphatase increased | Investigations | STA-9090 Cohort A | 0 | 1 | |
| serious | Alkaline phosphatase increased | Investigations | STA-9090 Cohort B | 1 | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | STA-9090 Cohort A | ||
| Total, all-cause mortality | STA-9090 Cohort B | ||
| Total, other adverse events | STA-9090 Cohort A | 0 | 1 |
| Total, other adverse events | STA-9090 Cohort B | 1 | 2 |
| Total, serious adverse events | STA-9090 Cohort A | 0 | 1 |
| Total, serious adverse events | STA-9090 Cohort B | 1 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| STA-9090 Cohort A vs STA-9090 Cohort B: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01551693
GET https://conductscience.org/api/trials/v1/NCT01551693/registered